WuXi XDC Cayman's revenue for the
three
months ended in Jun. 2023 was €65.2 Mil.
Its revenue for the trailing twelve months (TTM) ended in Jun. 2023 was €131.3 Mil.
WuXi XDC Cayman's Revenue per Share for the
three
months ended in Jun. 2023 was €0.06.
Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 was €0.11.
During the past 12 months, the average Revenue per Share Growth Rate of WuXi XDC Cayman was 129.50% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 181.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 4 years, WuXi XDC Cayman's highest 3-Year average Revenue per Share Growth Rate was 181.10% per year. The lowest was 181.10% per year. And the median was 181.10% per year.
WuXi XDC Cayman Revenue Historical Data
The historical data trend for WuXi XDC Cayman's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of WuXi XDC Cayman's Revenue
For the Diagnostics & Research subindustry, WuXi XDC Cayman's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WuXi XDC Cayman's Revenue Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, WuXi XDC Cayman's Revenue distribution charts can be found below:
* The bar in red indicates where WuXi XDC Cayman's Revenue falls into.
WuXi XDC Cayman Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €131.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WuXi XDC Cayman (FRA:L74) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
WuXi XDC Cayman Revenue Related Terms
Thank you for viewing the detailed overview of WuXi XDC Cayman's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
No. 11 Xinhui Ring Road, Xinwu, Jiangsu, Wuxi, CHN
Website
WuXi XDC Cayman Inc is a leading CRDMO focused on the global ADC and broader bioconjugate market and the only one dedicated to providing integrated and end-to-end services. Leveraging expertise in both biologics and small molecules, It offers interdisciplinary and comprehensive services, covering bioconjugate discovery, research, development and manufacturing. The company provides these services from proximately located, state-of-the-art laboratories and manufacturing facilities, leading to the significant reduction of development timeline and costs. As a fully integrated one-stop bioconjugate discovery, development and manufacturing platform, its mission is to continuously enhance its platform, and propel and transform the development of the bioconjugate industry.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:L74 has been successfully added to your